Top ▲

Diffuse large B-cell lymphoma

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:1254
Name:Diffuse large B-cell lymphoma
Associated with:1 target
2 immuno-relevant ligands
Synonyms
DLBCL | DLBL
Description
DLBCL is an aggressive lymphoproliferative malignancy that arises in the lymph nodes. It is the most common subtype of non-Hodgkin lymphoma in adults. DLBCL is classified as a rare disease.
Database Links
Disease Ontology: DOID:0050745

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols
CD37 molecule
Comments:  The anti-CD37 antibody conjugate naratuximab emtansine is an orphan drug that can be used in Europe and the US to treat patients with DLBCL.
Ligand interactions: 
Ligand Comments
naratuximab emtansine
Naratuximab emtansine is an EMA and FDA orphan drug that may be used to treat patients with DLBCL.
lilotomab
177Lu-lilotomab satetraxetan is a Phase 1 clinical candidate for relapsed/refractory DLBCL- see NCT02658968.

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
naratuximab emtansine 2-3
Immuno Disease Comments: Naratuximab emtansine is an EMA and FDA orphan drug that may be used to treat patients with DLBCL.
Clinical Use: Naratuximab emtansine (IMGN529) has completed Phase 1 clinical trial in patients with B cell malignancies (see NCT01534715) [4]. Naratuximab emtansine was granted EMA orphan designation for the treatment of diffuse large B cell lymphoma (DLBCL) in June 2015 [2], and by the FDA in May 2016 [3]. | View clinical data
Bioactivity Comments: The in vitro and in vivo (in NHL and CLL xenograft models) anti-tumour cell immune effector (intrinsic to the anti-CD37antibody) and anti-mitotic (due to the maytansinoid conjugate) activities of IMGN529 were reported by Deckert et al. in 2013 [1]. | View biological activity
lilotomab
Immuno Disease Comments: 177Lu-lilotomab satetraxetan is a Phase 1 clinical candidate for relapsed/refractory DLBCL- see NCT02658968.
Clinical Use: Click here to link to a complete list of lilotomab clinical studies that are registered at ClinicalTrials.gov. | View clinical data

References

Show »

1. Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, Mayo MF, Carrigan CN, Erickson HK, Pinkas J et al.. (2013) A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood, 122 (20): 3500-10. [PMID:24002446]

2. EMA. EU/3/15/1494 naratuximab emtansine orphan designation. Accessed on 11/05/2018. Modified on 11/05/2018. ema.europa.eu, http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2015/06/human_orphan_001581.jsp&mid=WC0b01ac058001d12b

3. FDA. Naratuximab emtansine orphan designation. Accessed on 11/05/2018. Modified on 11/05/2018. fda.gov, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=518016

4. Stathis A, Flinn IW, Madan S, Maddocks K, Freedman A, Weitman S, Zucca E, Munteanu MC, Lia Palomba M. (2018) Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Invest New Drugs, 36 (5): 869-876. [PMID:29453628]